Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIM447 and ribociclib combinations with ruxolitinib in myelofibrosis
NL-OMON44750Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PIM447, ribociclib and ruxolitinib in myelofibrosis (MF) (3 arms), sponsored by Novartis. Primary endpoint: Incidence of dose-limiting toxicities in cycle 1. Started Oct 2016; status: active, not recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON44750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44750.